Vasovagal Attack (Neurally Mediated Syncope) - Treatment

Pathophysiology in Brief

• Vasodepressor - hypotension predominates
• Cardioinhibitory - bradycardia/asystole predominates
• Mixed - most common; both bradycardia and vasodilation present

Acute Management

Long-Term Management (Recurrent Episodes)

1. Education and Lifestyle (First-line for all patients - Class I, Level C)

• Trigger avoidance: prolonged standing, hot environments, alcohol, dehydration, diuretics/vasodilators
• Recognize the prodrome and act (sit/lie down, perform counterpressure maneuvers)
• Increase salt and fluid intake (2-3 L/day), unless contraindicated (hypertension, heart failure)
• Compression stockings: lower extremity compression reduces venous pooling
• Education alone can significantly reduce syncope burden and traumatic injuries - Braunwald's Heart Disease, p. 693

2. Physical Counterpressure Maneuvers (Class IIa, Level B-R)

• Leg crossing with muscle tensing
• Isometric handgrip + arm tensing - 2 minutes at prodrome onset rendered ~2/3 of patients asymptomatic in tilt-table studies
• Effective and safe, especially for those with sufficient warning time
• A 2024 systematic review and meta-analysis (PMID 38181551) confirmed that physical counterpressure maneuvers, tilt training, and yoga all reduce vasovagal syncope recurrence

3. Orthostatic (Tilt) Training (Class IIb, Level B-R)

• Stand against a wall with heels 25 cm from wall, progressively increasing from 5 minutes twice daily to 40 minutes twice daily over 2-3 months
• Non-randomized studies are positive; randomized trials suggest only limited effectiveness
• Braunwald's Heart Disease, p. 693

Pharmacologic Treatment (for Refractory/Frequent Episodes)

Note on beta-blockers: Though historically used as first-line, recent trials have consistently shown metoprolol, propranolol, and nadolol to be no better than placebo in most patients. They retain a narrow indication in those over 42. - Braunwald's Heart Disease, p. 693

Device Therapy (Pacing)

• Age ≥40 years
• Recurrent vasovagal syncope
• Documented spontaneous cardioinhibitory response (≥3 seconds asystole, or ≥6-second pause without syncope) confirmed on implantable loop recorder

• The ISSUE-3 trial demonstrated a 57% reduction in 2-year syncope recurrence with dual-chamber pacing vs. sensing-only in this specific group
• The SPAIN study showed closed-loop stimulation (DDD-CLS) prolonged time to first recurrence of syncope sevenfold
• Earlier blinded RCTs (VPS, VPS II) showed no benefit - the difference lies in rigorous patient selection with documented asystole

Cardioneuroablation (Emerging)

Summary Algorithm

Vasovagal Syncope
       |
       ├─ Acute episode → Supine + legs elevated
       |
       └─ Recurrent prevention:
              ↓
       1. Education + trigger avoidance + hydration + salt ± stockings
              ↓ (if still recurrent)
       2. Physical counterpressure maneuvers (Class IIa)
              ↓ (if still recurrent)
       3. Midodrine (Class IIa) or Fludrocortisone (IIb)
              ↓ (if age ≥42, beta-blockers IIb)
       4. Pacemaker (Class IIb) — ONLY if ≥40 years + documented asystole
       5. Cardioneuroablation (investigational)

Can Duloxetine Be Given for Somatic Complaints? Yes - Here's the Evidence

Short Answer

Mechanism: Why Duloxetine Works for Somatic Complaints

• Descending pain inhibitory pathways from the brainstem to the spinal cord rely on both serotonin and norepinephrine
• NET inhibition amplifies noradrenergic signaling in these pathways, suppressing pain transmission at the dorsal horn
• SSRIs, which lack noradrenergic action, are generally not effective for somatic/visceral pain - this is why duloxetine and other SNRIs are preferred over SSRIs for painful conditions
• Sleisenger & Fordtran's GI and Liver Disease, p. 258

FDA-Approved Indications (Somatic/Pain)

Somatic Symptom Disorder (SSD) / Medically Unexplained Symptoms

• Chronic somatic anxiety is more responsive to MAOIs and SNRIs (duloxetine, venlafaxine) than to SSRIs - Kaplan & Sadock's Comprehensive Textbook of Psychiatry
• SNRIs are preferred over SSRIs for somatic complaints because the noradrenergic component directly targets pain pathways; SSRIs without this component have limited effect on somatic pain
• In somatic symptom disorder specifically, duloxetine addresses both the emotional (depression/anxiety) and physical (pain, fatigue) dimensions simultaneously

Dosing for Somatic Complaints

• Nausea is the predominant side effect; take with meals to reduce it
• Patients with painful conditions typically show response within the first week
• Dose reduction should be gradual (25% per week) when discontinuing to avoid withdrawal symptoms
• Sleisenger & Fordtran, Firestein & Kelley's Rheumatology

SNRIs vs. SSRIs for Somatic Complaints

Contraindications and Cautions

• Hepatic insufficiency: Duloxetine should be avoided (significant hepatic metabolism) - Firestein & Kelley's Rheumatology
• Hypertension monitoring: Dose-related BP increases reported
• Drug interactions: CYP450 2D6 inhibitors can alter plasma levels
• Black box warning: Increased suicidal ideation in patients under 25
• Serotonin syndrome risk if combined with other serotonergic drugs (MAOIs, triptans, tramadol)
• Platelet aggregation impairment: Caution with concurrent NSAIDs or aspirin

Recent Evidence